Program
NAV-240
A development code.
Its studies are mostly in Hidradenitis Suppurativa, led by Navigator Medicines.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Navigator Medicines | 31 open or running | phase 2since Jan 26, 2026 | Dec 13, 2023 | Sep 2027phase 2 · NCT07384975 |
Also a collaborator on its studies: southern-star-research and imbiologics-corp.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 13, 2023First study: phase 1 study in HealthyFirst studyNCT06181786 · 40 enrolled · United States
- Mar 31, 2025Phase 1 study in Healthy VolunteersNCT06933043 · 24 enrolled · Australia
- Jan 26, 2026Phase 2 study in Hidradenitis SuppurativaPhase 2 reachedNCT07384975 · 150 planned · United States, Bulgaria, Canada and more
Ahead
- Sep 2027Primary completion: phase 2 study in Hidradenitis SuppurativaNCT07384975
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07384975Hidradenitis Suppurativa · United States, Bulgaria, Canada and more | 2 | Recruiting | Sep 2027 | 150 |
| NCT06933043Healthy Volunteers · Australia | 1 | Completed | Nov 20, 2025 | 24 |
| NCT06181786Healthy · United States | 1 | Completed | Sep 4, 2024 | 40 |
How it is read
Names in the registry
- “NAV-240”, 3 entries
Codes read as this program: NAV240.
Conditions, from the studies’ own filings
- Hidradenitis Suppurativa, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.